AU2002235202A1 - Treatment of bone disorders by modulation of fgfr3 - Google Patents
Treatment of bone disorders by modulation of fgfr3Info
- Publication number
- AU2002235202A1 AU2002235202A1 AU2002235202A AU3520202A AU2002235202A1 AU 2002235202 A1 AU2002235202 A1 AU 2002235202A1 AU 2002235202 A AU2002235202 A AU 2002235202A AU 3520202 A AU3520202 A AU 3520202A AU 2002235202 A1 AU2002235202 A1 AU 2002235202A1
- Authority
- AU
- Australia
- Prior art keywords
- fgfr3
- modulation
- treatment
- bone disorders
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25588200P | 2000-12-18 | 2000-12-18 | |
| US60/255,882 | 2000-12-18 | ||
| US28569101P | 2001-04-24 | 2001-04-24 | |
| US60/285,691 | 2001-04-24 | ||
| US30687901P | 2001-07-23 | 2001-07-23 | |
| US60/306,879 | 2001-07-23 | ||
| US31797401P | 2001-09-10 | 2001-09-10 | |
| US60/317,974 | 2001-09-10 | ||
| PCT/US2001/048270 WO2002050246A2 (en) | 2000-12-18 | 2001-12-18 | Treatment of bone disorders by modulation of fgfr3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002235202A1 true AU2002235202A1 (en) | 2002-07-01 |
Family
ID=27500553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002235202A Abandoned AU2002235202A1 (en) | 2000-12-18 | 2001-12-18 | Treatment of bone disorders by modulation of fgfr3 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20040109850A1 (en) |
| AU (1) | AU2002235202A1 (en) |
| CA (1) | CA2432257A1 (en) |
| WO (1) | WO2002050246A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003287429A1 (en) * | 2002-11-01 | 2004-06-07 | Five Prime Therapeutics, Inc. | Stem cell libraries |
| EP2679600A1 (en) | 2009-03-25 | 2014-01-01 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
| CA2898415A1 (en) * | 2013-01-16 | 2014-07-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| JP6536871B2 (en) | 2013-12-02 | 2019-07-03 | 国立大学法人京都大学 | Preventive and therapeutic agent for FGFR3 disease and method of screening the same |
| PT3481859T (en) | 2016-07-07 | 2022-05-23 | Pfizer | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
| US20200297799A1 (en) * | 2017-09-20 | 2020-09-24 | Pfizer Inc. | Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides |
-
2001
- 2001-12-18 US US10/450,859 patent/US20040109850A1/en not_active Abandoned
- 2001-12-18 AU AU2002235202A patent/AU2002235202A1/en not_active Abandoned
- 2001-12-18 CA CA002432257A patent/CA2432257A1/en not_active Abandoned
- 2001-12-18 WO PCT/US2001/048270 patent/WO2002050246A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2432257A1 (en) | 2002-06-27 |
| WO2002050246A2 (en) | 2002-06-27 |
| WO2002050246A3 (en) | 2003-08-21 |
| US20040109850A1 (en) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001288628A1 (en) | Method and reagents for treatment of skin disorders by modulating the notch pathway | |
| WO2002086502A8 (en) | Methods for the diagnosis and treatment of bone disorders | |
| EP1059067B8 (en) | Ablation treatment of bone metastases | |
| AU2001275860A1 (en) | Surgical prep solution applicator system and methods | |
| AU2001261637A1 (en) | Apparatus for treatment of spinal disorders | |
| AU2001242450A1 (en) | Substances for the treatment of spinal muscular atrophy | |
| AU4165797A (en) | Methods and compositions for the treatment of bone resorption disorders, including osteoporosis | |
| AU2002342613A1 (en) | Treatment for wounds | |
| AU2002334870B8 (en) | Combinations for the treatment of immunoinflammatory disorders | |
| AUPR074500A0 (en) | Treatment of t cell disorders | |
| ZA200206318B (en) | Modulation of bone formation. | |
| WO2002039997A3 (en) | Ace-2 modulating compounds and use thereof | |
| AU2002245204A1 (en) | Methods for treating blood coagulation disorders | |
| AU2002319286A1 (en) | Skin treatment | |
| AU2001239510A1 (en) | Treatment of renal disorders | |
| AU2002235202A1 (en) | Treatment of bone disorders by modulation of fgfr3 | |
| AU3899100A (en) | Treatment of hyperactivity disorders | |
| AU2002258798A1 (en) | Methods for the treatment of hepatic disorders | |
| IL162053A0 (en) | Method for the treatment of bone disorders | |
| AU2001273759A1 (en) | Essential oils and chemically related species for the treatment of increased bone resorption | |
| AU2003266960A1 (en) | Composition for the treatment of pain, especially for the treatment of articular pain | |
| AU2002248484A1 (en) | Muscle-polymer constructs for bone tissue engineering | |
| WO2003048376A9 (en) | Modulation of immune-cell related disorders using il-1hy2 | |
| AU2001253560A1 (en) | Methods of treatment | |
| AU2002329838A1 (en) | Modulation of appl expression |